Lithium-related genetics of bipolar disorder

Annals of Medicine

Volumn 33, Issue 4, 2001, Pages 272-285

  Detera Wadleigh, S D ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Akt; Association; Expression profiling; Glycogen synthase kinase 3 ; IMPA2; Linkage; Protein kinase C; Single nucleotide polymorphisms; Susceptibility; Wnt

Indexed keywords

GENE PRODUCT; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; LITHIUM; PHOSPHATIDYLINOSITIDE;

AFFECTIVE NEUROSIS; CELL STRAIN; CELL SURVIVAL; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT PLANNING;

EID: 0034987265     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890108998756     Document Type: Review

References (121)

1. Burden of disease-implications for future research
2. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease survey
3. Initial sequencing and analysis of the human genome
4. The sequence of the human genome
5. John Cade: The man
6. An economic evaluation of manic-depressive illness - 1991
7. The impact of the discovery of lithium on psychiatric thought and practice in the USA and Europe
8. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder
9. Does lithium treatment still work? Evidence of stable response over three decades
10. Forty years of lithium treatment
11. Discrepancies in the efficacy of lithium
12. Mortality of patients who dropped out from regular lithium prophylaxis: A collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI)
13. The lithium ion: A foundation for psychopharmacological specificity
14. 1H-magnetic resonance spectroscopy in bipolar disorder
15. Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: Relationship to erythrocyte and serum concentrations
16. (7)Li NMR in biomedicine
17. (7)Li magnetic resonance spectroscopy (MRS): A literature review
18. Anti-bipolar therapy: Mechanism of action of lithium
19. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness
20. Overview of the mechanism of action of lithium in the brain: Fifity-year update
21. Lithium therapy and signal transduction
22. Neural and developmental actions of lithium: A unifying hypothesis
23. Cloning, heterologous expression, and chromosomal localization of human inositol polyphosphate 1-phosphatase
24. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA)
25. A novel human myo-inositol monophosphatase gene, IMP.18p, maps to a susceptibility region for bipolar disorder
26. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1)
27. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants
28. cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme
29. Inositol monophosphatase, the putative therapeutic target for lithium
30. Mechanism of inositol monophosphatase, the putative target of lithium therapy
31. Structure of inositol monophosphatase, the putative target of lithium therapy
32. Chromosome 18 DNA markers and manic-depressive illness: Evidence for a susceptibility gene
33. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2
34. Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2)
35. A human myo-inositol monophosphatase gene (IMPA2) in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: Genomic structure and polymorphic screening in manic-depressive patients
36. +-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure
37. A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3′-phosphoadenosine 5′-phosphate phosphatase and inositol-polyphosphate 1-phosphatase
38. Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3′-nucleotidase inhibited by inositol 1,4-bisphosphate
39. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania
40. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy
41. Behavioral reversal of lithium effects by four inositol isomer correlates perfectly with biochemical effects on the PI cycle: Deletion by chronic lithium of brain inositol is specific to hypothalamus, and inositol levels may be abnormal in postmortem brain from bipolar patients
42. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness
43. Lithium decreases Gs, Gi-1 and Gi-2 alpha-subunit mRNA levels in rat cortex
44. Chronic lithium regulates the expression of adenylate cyclase and Gi-protein alpha subunit in rat cerebral cortex
45. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain
46. The involvement of guanine nucleotide binding proteins in the pathogenesis and treatment of affective disorders
47. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode
48. Enhanced protein kinase C activity and translocation in bipolar affective disorder
49. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania
50. Loss of prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate
51. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs
52. A molecular mechanism for the effect of lithium on development
53. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
54. WNT-7a induces axonal remodeling and increase synapsin I levels in cerebellar neurons
55. Radiation hybrid mapping of genes in the lithium-sensitive Wnt signaling pathway
56. A large family of putative transmembrane receptors homologous to the product of the Drosophila tissue polarity gene frizzled
57. Negative regulation of Armadillo, a Wingless effector in Drosophila
58. Stabilization of beta-catenin by genetic defects in melanoma cell lines
59. SARPs: A family of secreted apoptosis-related proteins
60. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
61. Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain
62. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients
63. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx
64. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity
65. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
66. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells
67. Akt signaling: Linking membrane events to life and death decisions
68. Regulation of neuronal survival by the serine-threonine protein kinase Akt
69. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
70. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
71. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration
72. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway
73. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium
74. Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells
75. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C
76. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes
77. Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a protein kinase C
78. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity
79. Scratching the surface with the PH domain
80. Relationship between the effectiveness of Li Rx and family history
81. Factors associated with response to lithium prophylaxis in DSM-III major depression and bipolar disorder
82. Lithium response and genetics of affective disorders
83. Relationship between prophylactic effect of lithium therapy and family history of affective disorders
84. Family history of affective disorders and the significance for prophylactic effect of lithium treatment
85. Family history and symptom levels during treatment for bipolar I affective disorder
86. Mode of inheritance in families of patients with lithium responsive affectgive disorders
87. Autosomal recessive inheritance of affective disorders in families of responders to lithium prophylaxis?
88. Segregation and linkage analyses in families of patients with bipolar, unipolar, and schizoaffective mood disorders
89. A locus for bipolar affective disorder on chromosome 4p
90. A susceptibility locus for bipolar affective disorder on chromosome 4q35
91. Genome-wide search for linkage of bipolar affective disorders in a very large pedigree derived from a homogeneous population in quebec points to a locus of major effect on chromosome 12q23-q24
92. An apparently dominant bipolar affective disorder (BPAD) locus on chromosome 20p11.2-q11.2 in a large Turkish pedigree
93. A complete genome screen for genes pre-disposing to severe bipolar disorder in two Costa Rican pedigrees
94. Genomic survey of bipolar illness in the NIMH genetics initiative pedigrees: A preliminary report
95. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22
96. Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect
97. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23
98. Lithium responsive bipolar disorder, unilineality, and chromosome 18: A linkage study
99. A haplotype-based study of lithium responding patients with bipolar affective disorder on the Faroe Islands
100. MAOA: Association and linkage studies with lithium responsive bipolar disorder
101. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder
102. Association and linkage studies of CRH and PENK genes in bipolar disorder: A collaborative IGSLI study
103. Polyglutamine coding genes in bipolar disorder: Lack of association with selected candidate loci
104. Lithium-responsive affective disorders: No association with the tyrosine hydroxylase gene
105. Dopamine receptor D2 and D4 genes, GABA (A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders
106. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders
107. The future of genetic studies of complex human diseases
108. Genetic epidemiology of single nucleotide polymorphisms
109. Predicting the range of linkage disequilibrium
110. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase
111. Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium
112. Evidence for association of the myoinositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples
113. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder
114. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness
115. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis
116. Do schizophrenia and affective disorder share susceptibility genes?
117. Association study designs for complex diseases
118. Experimental annotation of the human genome using microarray technology
119. Proteomics in genomeland
120. Lithium ions up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cells
121. A map of human sequence variation containing 1.42 million single nucleotide polymorphisms